Pharmacokinetic and Pharmacodynamic Assessment of Oral Valganciclovir in the Treatment of Symptomatic Congenital Cytomegalovirus Disease
The Journal of Infectious Diseases2008Vol. 197(6), pp. 836–845
Citations Over TimeTop 1% of 2008 papers
David W. Kimberlin, Edward P. Acosta, Pablo J. Sánchez, Sunil K. Sood, Vish Agrawal, James Homans, Richard F. Jacobs, David J. Lang, José R. Romero, Jill Griffin, Gretchen A. Cloud, Fred D. Lakeman, Richard J. Whitley
Abstract
In neonates with symptomatic congenital CMV disease, valganciclovir oral solution provides plasma concentrations of ganciclovir comparable to those achieved with administration of intravenous ganciclovir. The results of the present study cannot be extrapolated to extemporaneously compounded liquid formulations of valganciclovir.
Related Papers
- → Oral Valganciclovir Is Noninferior to Intravenous Ganciclovir for the Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients(2007)423 cited
- → Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients(2006)65 cited
- → Use of High-Dose Ganciclovir for the Treatment of Cytomegalovirus Replication in Solid Organ Transplant Patients With Ganciclovir Resistance-Inducing Mutations(2013)54 cited
- → Ganciclovir penetrates into the cerebrospinal fluid of an infant with congenital cytomegalovirus infection(2015)8 cited
- [Valganciclovir. Oral treatment of Cytomegalovirus infections].(2004)